Related Experiment Video

Updated: Jun 16, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Rewriting microenvironment immunity in glioblastoma

John W Figg1, Catherine T Flores1

  • 1Preston A. Wells, Jr Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.

Molecular Therapy. Oncology
|June 15, 2026
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Related Experiment Videos

Last Updated: Jun 16, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Articles linked to this work by shared authors, journal, and citation graph.

Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer Immunotherapy.

Cancers·2026

Myeloid-Derived Suppressor Cells: Function, Migration, and Therapeutic Opportunities in Glioblastoma.

Cells·2026

Adoptive cellular therapy prevents reconstitution of myeloid-derived suppressor cells in the glioma tumor microenvironment.

Neuro-oncology advances·2026

Benzodiazepines at the crossroads: navigating therapeutic promise and perils of misuse.

Annals of general psychiatry·2026

Radial glial cells and glioblastoma: how developmental neurobiology can inform our understanding of brain cancer initiation, treatment resistance, and resilience.

Translational oncology·2025

Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading.

Nature biomedical engineering·2025

Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes.

Molecular therapy. Oncology·2026

Targeting AATF reprograms the tumor microenvironment and suppresses hepatocellular carcinoma via MIR100HG-TGF-β signaling.

Molecular therapy. Oncology·2026

Intramuscular plasmid DNA electroporation sequesters neoantigen-specific CD8<sup>+</sup> T cells in treated muscle and limits tumor infiltration.

Molecular therapy. Oncology·2026

Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.

Molecular therapy. Oncology·2026

A novel combination approach targeting P300 and DNA-PK exploits epigenetic dependencies in acute myeloid leukemia.

Molecular therapy. Oncology·2026

Anti-myeloma mechanisms of the selective NF-κB inhibitor QNZ.

Molecular therapy. Oncology·2026

Innate Immune Memory Responses in Organ Transplantation.

Arteriosclerosis, thrombosis, and vascular biology·2026

Complicated Jejunal Diverticulosis as a Rare Cause of Small Bowel Perforation in an Immunocompromised Patient: A Case Report.

Cureus·2026

10-HDA attenuates inflammatory responses in LPS-activated RAW264.7 cells <i>in vitro</i> via the NUR77/NF-κB pathways and improving mitochondrial functions.

Frontiers in pharmacology·2026

The IL-10-producing NKT10 subset plays a critical role in preventing graft-versus-host-disease.

Frontiers in immunology·2026

Life-threatening multiorgan immune-related toxicities complicated by sepsis after anti-PD-1 therapy with complete tumor regression: a case report and literature review.

Frontiers in immunology·2026

The multifaceted role of NF-κB signaling in psoriasis: from inflammatory amplification to epidermal remodeling.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us